Eli Lilly taps Fujifilm to chip in on COVID-19 antibody manufacturing as it awaits FDA's emergency use decision

Eli Lilly
Eli Lilly filed its COVID-19 antibody for the FDA's emergency use authorization last week. (Eli Lilly)

Shortly after rolling out interim data on its COVID-19 antibody hopeful, Eli Lilly last week sent the therapy ahead to the FDA for a potential emergency nod. If the antibody crosses the finish line, Lilly can expect a huge surge in demand—and it's bringing in a manufacturing partner to help out. 

Lilly has signed on Fujifilm Diosynth Biotechnologies to rev up manufacturing of one of its COVID-19 antibodies for distribution to low- and middle-income countries, the Japanese manufacturer said last week. 

Fujifilm will reserve production capacity at its Hillerød, Denmark biologics site, with commercial manufacturing set to begin in April, the company said. The facility holds six 20,000-liter bioreactors and will double in capacity as part of a $928M expansion project announced in June.

Upcoming Webinar

Lifecycle Management Strategies Targeted For Patient Populations with Swallowing Disorders

Hear from industry experts as they discuss life cycle management strategies for patients with swallowing disorders and the overall impact on patient perception. The webinar will include several panel speakers representing different perspectives and case study examples. Save your spot and register today!

The agreement falls under the umbrella of the Bill and Melinda Gates Foundation-funded COVID-19 Therapeutics Accelerator, which aims to distribute affordable therapeutics to developing nations. 

RELATED: Eli Lilly rushes to FDA with its COVID-19 antibody for emergency green light, reveals new cocktail therapy data

Suggested Articles

Creating a relevant online health user experience has its payoffs — for both the user and the brand. Here’s why.

Sanofi's new strategy delivered for the drugmaker in the third quarter as Dupixent posted blockbuster sales and flu vaccines set a revenue record.

Catalent has acquired Bone Therapeutics' cell and gene therapy site in Gosselies, Belgium, to add to its growing "center of excellence" there.